During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local ...

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be ...

The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...

Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor ...

Panelists discuss how the importance of AEGEAN approval lies in its potential to enhance patient treatment options, paving ...

Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of ...